SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor - Hoffmann, M; Kleine-Weber, H; Schroeder, S (Cell, 2020)
et al.